Application No.: 10/594,740 Docket No.: 3493-0179PUS1

## **AMENDMENTS TO THE CLAIMS**

## 1.-10. (Cancelled)

- 11. (Previously Presented) A process for the preparation of a soluble inclusion compound comprising one or more active substances included in one or more host molecules, the active substance or substances not being very soluble in an aqueous medium, wherein it comprises the following successive stages:
- a. bringing one or more active substances into contact with one or more host molecules,
- b. carrying out a stage of molecular diffusion by bringing a dense pressurized fluid into contact, in static mode, with the mixture obtained in stage (a) in the presence of one or more diffusion agents,
  - c. recovering the active substance/host molecule molecular complex thus formed,
- d. carrying out a stage which consists in adding to and mixing with the active substance/host molecular complex an agent for interaction with the complex,
  - e. recovering the soluble inclusion compound thus formed.
- 12. (Currently Amended) The process as claimed in claim 11, wherein the host molecule is chosen from the group consisting of saccharides or polysaccharides or their mixtures, preferably from cyclodextrins and their mixture.
- 13. (Previously Presented) The process as claimed in claim 11, wherein the agent for interaction with the complex is an acid or a base.
- 14. (Previously Presented) The process as claimed in claim 13, wherein the agent for interaction with the complex is an amino acid, a carboxylic acid or aqueous ammonia.
- 15. (Previously Presented) The process as claimed in claim 11, wherein the dense pressurized fluid is carbon dioxide.

Application No.: 10/594,740 Docket No.: 3493-0179PUS1

16. (Previously Presented) The process as claimed in claim 11, wherein the active substance is a pharmaceutical active principle, a cosmetic active principle or a nutraceutic active principle.

- 17. (Previously Presented) The process as claimed in claim 16, wherein the active substance is chosen from the group consisting of anilide derivatives, epipodophyllotoxin derivatives, minoxidil, piroxicam, valeric acid, octanoic acid, lauric acid, stearic acid, tiaprofenic acid, omeprazole, econazole, miconazole, ketoconazole, astemizole, cyclobenzaprine, nimesulide, ibuprofen, terfenadine, domperidone, naproxen and eflucimibe.
- 18. (Previously Presented) The process as claimed in claim 11, wherein the pressure of the dense fluid is between 0.5 Mpa and 50 MPa and the temperature between 0 and 200°C.
- 19.(Previously Presented) The process as claimed in claim 11, wherein the diffusion agent is chosen from the group consisting of alcohols, ketones, ethers, esters and water, with or without surfactant, and their mixtures.
- 20. (Previously Presented) The process as claimed in claim 11, wherein stage (b) of molecular diffusion is carried out with stirring.
- 21. (Currently Amended) The process as claimed in claim 11, wherein the diffusion agent is added continuously or portionwise in an amount of between 1 and 50% by weight <u>with</u> <u>respect to the total weight</u>.
  - 22. 25. (Cancelled)
- 26. (New) The process as claimed in claim 12, wherein the host molecule is selected from the group consisting of cyclodextrins and their mixture.